Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium 2022

Written by Petra Hegmann on 30th November 2021. Posted in Client News.